Form 4: InspireMD Director Michael Berman Receives Equity Grant

InspireMD, Inc. Director Michael Berman was granted 88,053 shares of restricted common stock, vesting on January 14, 2027.

Summary

• InspireMD, Inc. Director Michael Berman acquired 88,053 shares of common stock on January 14, 2026.
• These shares are restricted stock and will vest on January 14, 2027, contingent upon Mr. Berman's continued service to the company.
• The acquisition price for these restricted shares was $0.
• Following this transaction, Michael Berman directly beneficially owns 352,586 shares of common stock.
• Additionally, Mr. Berman indirectly beneficially owns 244,994 shares of common stock through the Michael Berman Revocable Trust, for which no transaction was reported in this filing.
• The total beneficial ownership reported by Michael Berman is 597,580 shares (352,586 direct + 244,994 indirect).

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is generally positive for corporate governance and aligns management interests with shareholders. It is not a major operational or financial event but reflects standard compensation practices.

Positives

• The grant of restricted stock aligns the director's long-term interests with those of the shareholders, promoting sustained commitment and performance.
• Equity compensation is a common and effective method for retaining key personnel and incentivizing long-term value creation.

Negatives

• The shares are restricted and do not provide immediate liquidity or full ownership until the vesting date.
• Vesting is subject to continued service, meaning the shares could be forfeited if the director's service ceases before January 14, 2027.

Risks

• The vesting of the 88,053 restricted shares is contingent upon Michael Berman's continued service to InspireMD, Inc. until January 14, 2027.

Future Outlook

The filing indicates a future vesting event for the restricted stock on January 14, 2027, contingent on the director's continued service. No other forward-looking statements or guidance are provided.

Industry Context

The grant of restricted stock to a director is a standard practice in the medical device and broader corporate sectors for executive and director compensation. It is designed to align the interests of leadership with long-term shareholder value creation, a common trend across publicly traded companies.

Comparison to Industry Standards

• Equity grants, particularly restricted stock, are a prevalent component of director compensation packages across various industries, including medical technology. This practice is consistent with global benchmarks for corporate governance and executive incentive structures.
• The vesting schedule, typically over one to several years, is also standard, aiming to ensure sustained commitment from directors. Specific comparable companies or projects are not detailed in this filing, but the general approach aligns with industry norms for director equity compensation.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of 88,053 shares of restricted common stock by Michael Berman, a director of InspireMD, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, potentially fostering decisions that benefit the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 88,053 restricted shares are scheduled to vest on January 14, 2027, subject to Michael Berman's continued service.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to a director, which is a standard compensation practice designed to align management interests with shareholders. It does not provide new information that would alter the fundamental investment thesis for InspireMD, Inc., hence a 'hold' recommendation is maintained based solely on this filing.

Keywords

InspireMD, NSPR, Michael Berman, restricted stock, common stock, insider transaction, director compensation, equity grant, SEC Form 4